Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors
Abstract
No abstract availableKeywords
Funding Information
- NIH (AI0078859, AI0074410, NS070740, NS060632)
This publication has 99 references indexed in Scilit:
- HIV-1 Tat Assembles a Multifunctional Transcription Elongation Complex and Stably Associates with the 7SK snRNPMolecular Cell, 2010
- Inhibition of human immunodeficiency virus type-1 by cdk inhibitorsAIDS Research and Therapy, 2010
- Glycogen synthase kinase-3β (GSK-3β) inhibitors AR-A014418 and B6B3O prevent human immunodeficiency virus-mediated neurotoxicity in primary human neuronsJournal of NeuroVirology, 2009
- Active β-Catenin Signaling Is an Inhibitory Pathway for Human Immunodeficiency Virus Replication in Peripheral Blood Mononuclear CellsJournal of Virology, 2008
- CDK inhibitors in cancer therapy: what is next?Trends in Pharmacological Sciences, 2008
- Human Immunodeficiency Virus-Restricted Replication in Astrocytes and the Ability of Gamma Interferon To Modulate This Restriction Are Regulated by a Downstream Effector of the Wnt Signaling PathwayJournal of Virology, 2007
- Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and TherapeuticsNeurochemical Research, 2006
- HIV-1 Tat Causes Apoptotic Death and Calcium Homeostasis Alterations in Rat NeuronsBiochemical and Biophysical Research Communications, 2001
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000
- Glycogen synthase kinase-3: functions in oncogenesis and developmentBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1992